NewLink Genetics Corporation (NASDAQ:NLNK) saw a large growth in short interest in September. As of September 15th, there was short interest totalling 7,917,401 shares, a growth of 42.7% from the August 31st total of 5,547,335 shares. Approximately 36.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 9,112,435 shares, the days-to-cover ratio is presently 0.9 days.

Several equities analysts have recently commented on NLNK shares. Cantor Fitzgerald set a $32.00 target price on shares of NewLink Genetics Corporation and gave the company a “buy” rating in a research report on Sunday, June 4th. Zacks Investment Research upgraded shares of NewLink Genetics Corporation from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Wednesday, June 7th. Jefferies Group LLC upgraded shares of NewLink Genetics Corporation from a “hold” rating to a “buy” rating and boosted their target price for the company from $7.00 to $26.00 in a research report on Friday, September 8th. Stifel Nicolaus boosted their target price on shares of NewLink Genetics Corporation from $14.00 to $29.00 and gave the company a “buy” rating in a research report on Monday, September 11th. Finally, Robert W. Baird cut shares of NewLink Genetics Corporation from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $25.00 to $8.00 in a research report on Thursday, June 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $24.17.

A number of institutional investors have recently made changes to their positions in NLNK. State of Wisconsin Investment Board bought a new stake in NewLink Genetics Corporation during the second quarter valued at approximately $125,000. Trexquant Investment LP lifted its position in NewLink Genetics Corporation by 39.1% during the second quarter. Trexquant Investment LP now owns 18,132 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 5,097 shares during the last quarter. Advisor Group Inc. lifted its position in NewLink Genetics Corporation by 3.4% during the second quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 600 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in NewLink Genetics Corporation by 3.0% during the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 556 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in NewLink Genetics Corporation during the second quarter valued at approximately $165,000. Institutional investors and hedge funds own 54.78% of the company’s stock.

NewLink Genetics Corporation (NLNK) opened at 9.16 on Thursday. The firm’s market capitalization is $269.50 million. NewLink Genetics Corporation has a 52-week low of $5.90 and a 52-week high of $25.17. The company’s 50-day moving average is $8.77 and its 200-day moving average is $12.66.

NewLink Genetics Corporation (NASDAQ:NLNK) last announced its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.21. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. The business had revenue of $10.37 million during the quarter, compared to analyst estimates of $2.65 million. Analysts forecast that NewLink Genetics Corporation will post ($2.82) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/09/28/short-interest-in-newlink-genetics-corporation-nlnk-grows-by-42-7.html.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Receive News & Stock Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related stocks with our FREE daily email newsletter.